Anti-CD38 Monoclonal Antibody

DRUG2 trials

Sponsors

University of Turin, Italy, Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Conditions

AmyloidosisMultiple Myeloma

Phase 1

A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma

Not yet recruitingNCT07090954

Genrix (Shanghai) Biopharmaceutical Co., Ltd.Multiple Myeloma

Start: 2025-08-31End: 2030-01-31Target: 32Updated: 2025-07-29

Unknown Phase

AL Amyloidosis and Anti-CD38-Daratunumab

CompletedNCT06571864

University of Turin, ItalyAmyloidosis

Start: 2022-01-02End: 2024-02-02Updated: 2024-08-26